financetom
Business
financetom
/
Business
/
Rocket Pharmaceuticals' Gene Therapy for Inherited Heart Disease Receives Orphan Drug Designation in Europe
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rocket Pharmaceuticals' Gene Therapy for Inherited Heart Disease Receives Orphan Drug Designation in Europe
May 29, 2024 5:37 AM

08:00 AM EDT, 05/29/2024 (MT Newswires) -- Rocket Pharmaceuticals ( RCKT ) said Wednesday that it received orphan medicinal product designation from the European Commission for RP-A601, its gene therapy for plakophilin-2-related arrhythmogenic cardiomyopathy, or PKP2-ACM.

The designation is based on the European Medicines Agency's positive opinion, the company said.

Orphan designation provides financial and regulatory benefits, including protocol assistance from the EMA during clinical development, centralized marketing authorization access, and 10 years of marketing exclusivity following product approval, the company said.

Rocket Pharmaceuticals ( RCKT ) is enrolling patients in a phase 1 trial to evaluate the safety and efficacy of RP-A601 for high-risk PKP2-ACM patients.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lichen China Launches $3.4 Million Registered Direct Offering
Lichen China Launches $3.4 Million Registered Direct Offering
Jan 28, 2025
01:19 PM EST, 01/28/2025 (MT Newswires) -- Lichen China ( LICN ) said Tuesday it has signed an agreement with certain investors for a $3.4 million registered direct offering of class A ordinary shares. The offering includes 42.5 million shares at $0.08 apiece, according to the company. Lichen said it expects to close the offering on or about Jan. 29....
Ares Management Participates in ABN Amro Originated $1.36 Billion Loan Portfolio
Ares Management Participates in ABN Amro Originated $1.36 Billion Loan Portfolio
Jan 28, 2025
01:18 PM EST, 01/28/2025 (MT Newswires) -- Ares Management ( ARES ) through its alternative credit funds, and ABN Amro entered into a collaboration to manage a 1.3 billion euros ($1.36 billion) loan portfolio, ABN Amro said Tuesday. Ares will join a portfolio of high-quality senior secured infrastructure loans sourced by ABN Amro across Europe, helping ABN Amro optimize its...
BRIEF-ExGen Signs Purchase Agreement To Acquire Spark North Lithium Project In Nevada
BRIEF-ExGen Signs Purchase Agreement To Acquire Spark North Lithium Project In Nevada
Jan 28, 2025
Jan 28 (Reuters) - ExGen Resources Inc ( BXXRF ): * EXGEN SIGNS PURCHASE AGREEMENT TO ACQUIRE SPARK NORTH LITHIUM PROJECT IN NEVADA Source text: Further company coverage: ;)) ...
Genpact Launches AI Gigafactory
Genpact Launches AI Gigafactory
Jan 28, 2025
01:04 PM EST, 01/28/2025 (MT Newswires) -- Genpact ( G ) said Tuesday it has launched the Genpact AI Gigafactory to help enterprises scale AI solutions from pilot to full-scale production. The firm said it aims to create a pool of over 25,000 AI builders. Genpact ( G ) shares were up about 3% in recent trading. Price: 47.75, Change:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved